Skip to main content
SpringerLink
Log in

Ixekizumab

  • Chapter
  • First Online:
Advances in Psoriasis

  • 611 Accesses

Abstract

Ixekizumab is a fully human monoclonal antibody that selectively targets IL-17A which has shown to be highly effective in the treatment of psoriasis and psoriatic arthritis. This chapter reviews the efficacy and safety profile of ixekizumab for the treatment of psoriasis based on clinical studies to date. Studies demonstrate that ixekizumab is highly effective in the treatment of moderate-to-severe psoriasis and the majority of patients achieve high clearance rates. Uncommon adverse events reported during ixekizumab therapy, included neutropenia, candida infections, and inflammatory bowel disease, however long-term safety data beyond 5 years is not yet available.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Liu L, Lu J, Allan BW, Tang Y, Tetreault J, Chow CK, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Leonardi CL, Blauvelt A, Sofen HL, Gooderham M, Augustin M, Burge R, et al. Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3. J Eur Acad Dermatol Venereol. 2017;31(9):1483–90.

    Article  CAS  PubMed  Google Scholar 

  3. Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–56.

    Article  CAS  PubMed  Google Scholar 

  4. Blegvad C, Skov L, Zachariae C. Ixekizumab for the treatment of psoriasis: an update on new data since first approval. Expert Rev Clin Immunol. 2019;15(2):111–21.

    Article  CAS  PubMed  Google Scholar 

  5. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125521s009lbl.pdf

  6. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361(9):888–98.

    Article  CAS  PubMed  Google Scholar 

  7. Stark MA, Huo Y, Burcin TL, Morris MA, Olson TS, Ley K. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity. 2005;22(3):285–94.

    Article  CAS  PubMed  Google Scholar 

  8. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol. 2010;10(7):479–89.

    Article  CAS  PubMed  Google Scholar 

  9. Gisondi P, Geat D, Pizzolato M, Girolomoni G. State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis. Curr Opin Pharmacol. 2019;46:90–9.

    Article  CAS  PubMed  Google Scholar 

  10. http://www.medicines.org.uk/emc/product/7233/smpc

  11. Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–51.

    Article  CAS  PubMed  Google Scholar 

  12. Farahnik B, Beroukhim K, Zhu TH, Abrouk M, Nakamura M, Singh R, et al. Ixekizumab for the treatment of psoriasis: a review of phase III trials. Dermatol Ther. 2016;6(1):25–37.

    Article  Google Scholar 

  13. Reich K, Puig L, Mallbris L, Zhang L, Osuntokun O, Leonardi C. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled phase 3 studies of patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(7):1196–207.

    Article  CAS  PubMed  Google Scholar 

  14. O’Rielly DD, Rahman P. A review of ixekizumab in the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(12):993–1002.

    Article  PubMed  Google Scholar 

  15. Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79–87.

    Article  CAS  PubMed  Google Scholar 

  16. Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317–27.

    Article  CAS  PubMed  Google Scholar 

  17. Van de Kerkhof P, Guenther L, Gottlieb AB, Sebastian M, Wu JJ, Foley P, et al. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3. J Eur Acad Dermatol Venereol. 2017;31(3):477–82.

    Article  PubMed  CAS  Google Scholar 

  18. Blauvelt A, Muram TM, See K, Mallinckrodt CH, Crowley JJ, van de Kerkhof P. Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab. J Dermatol Treat. 2018;29(3):220–9.

    Article  CAS  Google Scholar 

  19. Rich P, Bourcier M, Sofen H, Fakharzadeh S, Wasfi Y, Wang Y, PHOENIX 1 Investigators, et al. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. Br J Dermatol. 2014;170(2):398–407.

    Article  CAS  PubMed  Google Scholar 

  20. Luger TA, Barker J, Lambert J, Yang S, Robertson D, Foehl J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2009;23(8):896–904.

    Article  CAS  PubMed  Google Scholar 

  21. Ortonne JP, Paul C, Berardesca E, Marino V, Gallo G, Brault Y, et al. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. Br J Dermatol. 2013;168(5):1080–7.

    Article  CAS  PubMed  Google Scholar 

  22. Reich K, Leonardi C, Lebwohl M, Kerdel F, Okubo Y, Romiti R, et al. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). J Dermatol Treat. 2017;28(4):282–7.

    Article  CAS  Google Scholar 

  23. Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol. 2003;49(2):271–5.

    Article  PubMed  Google Scholar 

  24. Chung J, Duffin KC, Takeshita J, Shin DB, Krueger GG, Robertson AD, et al. Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2014;71(4):623–32.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Leonardi C, Langley RG, Papp K, Tyring SK, Wasel N, Vender R, et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol. 2011;147(4):429–36.

    Article  CAS  PubMed  Google Scholar 

  26. Menter A, Warren RB, Langley RG, Merola JF, Kerr LN, Dennehy EB, et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). J Eur Acad Dermatol Venereol. 2017;31(10):1686–92.

    Article  CAS  PubMed  Google Scholar 

  27. Ryan C, Menter A, Guenther L, Blauvelt A, Bissonnette R, Meeuwis K, et al. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase III b study of patients with moderate-to-severe genital psoriasis. Br J Dermatol. 2018;179(4):844–52.

    Article  CAS  PubMed  Google Scholar 

  28. Jemec GB, Baadsgaard O. Effect of cyclosporine on genital psoriasis and lichen planus. J Am Acad Dermatol. 1993;29(6):1048–9.

    Article  CAS  PubMed  Google Scholar 

  29. Martín GE, Sánchez MR, Herrera EA, Umbert PM. Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques. J Drugs Dermatol. 2006;5(4):334–6.

    Google Scholar 

  30. Rallis E, Nasiopoulou A, Kouskoukis C, et al. Successful treatment of genital and facial psoriasis with tacrolimus 0.1%. Drugs Exp Clin Res. 2005;31(4):141–5.

    CAS  PubMed  Google Scholar 

  31. Saeki H, Nakagawa H, Nakajo K, Ishii T, Morisaki Y, Aoki T, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44(4):355–62.

    Article  CAS  PubMed  Google Scholar 

  32. Langley RG, Kimball AB, Nak H, Xu W, Pangallo B, Osuntokun OO, et al. Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials. J Eur Acad Dermatol Venereol. 2019;33(2):333–9.

    Article  CAS  PubMed  Google Scholar 

  33. Strober B, Leonardi C, Papp KA, Mrowietz U, Ohtsuki M, Bissonnette R, et al. Short-and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: etanercept comparisons and integrated data. J Am Acad Dermatol. 2017;76(3):432–40.

    Article  CAS  PubMed  Google Scholar 

  34. Castro KG, Goldberg S, Jereb JA, LoBue P, Mazurek GH, Vernon A. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep. 2010;59(RR-5):1–25.

    PubMed  Google Scholar 

  35. Canadian tuberculosis standards, Vol. 469, 7th edn. Ottawa: Public Health Agency of Canada; 2014.

    Google Scholar 

  36. Tsiouri G, Gaitanis G, Kiorpelidou D, Dionysiou A, Efthymiou A, Daskalopoulos G, et al. Tuberculin skin test overestimates tuberculosis hypersensitivity in adult patients with psoriasis. Dermatology. 2009;219(2):119–25.

    Article  CAS  PubMed  Google Scholar 

  37. Skroza N, Proietti I, Pampena R, La Viola G, Bernardini N, Nicolucci F, et al. Correlations between psoriasis and inflammatory bowel diseases. Biomed Res Int. 2013;2013:983902.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008;28(4):454–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn’s disease. J Eur Acad Dermatol Venereol. 2009;23(5):561–5.

    Article  CAS  PubMed  Google Scholar 

  40. Egeberg A, Mallbris L, Warren RB, Bachelez H, Gislason GH, Hansen PR, et al. Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. Br J Dermatol. 2016;175(3):487–92.

    Article  CAS  PubMed  Google Scholar 

  41. Reich K, Leonardi C, Langley RG, Warren RB, Bachelez H, Romiti R, et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2017;76(3):441–8.

    Article  CAS  PubMed  Google Scholar 

  42. Griffiths CE, Fava M, Miller AH, Russell J, Ball SG, Xu W, et al. Impact of ixekizumab treatment on depressive symptoms and systemic inflammation in patients with moderate-to-severe psoriasis: an integrated analysis of three phase 3 clinical studies. Psychother Psychosom. 2017;86(5):260–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Dermatologists Ireland, Dublin, Ireland

    Caitriona Ryan

  2. Charles Institute of Dermatology, University College Dublin, Dublin, Ireland

    Caitriona Ryan

  3. Department of Dermatology, Children’s Health Ireland (CHI) at Crumlin, Dublin, Ireland

    Roisin O’Connor

Authors
  1. Caitriona Ryan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roisin O’Connor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Caitriona Ryan .

Editor information

Editors and Affiliations

  1. Department of Dermatology, Suite 11D, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Jeffrey M. Weinberg

  2. Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Mark Lebwohl

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ryan, C., O’Connor, R. (2021). Ixekizumab. In: Weinberg, J.M., Lebwohl, M. (eds) Advances in Psoriasis. Springer, Cham. https://doi.org/10.1007/978-3-030-54859-9_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-54859-9_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-54858-2

  • Online ISBN: 978-3-030-54859-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation